Physician profile
Salvatore Dangelo
NPI 1245215664
$3,151.08
in general payments reported to CMS, 2019-2025
13 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $215 · 2021: $407 · 2023: $627 · 2024: $215 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $848.34 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $506.17 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $297.47 | 2024-2025 | |
| Shire North American Group INC | $243.74 | 2019 | |
| Genentech USA, INC. | $235.31 | 2019 | |
| Csl Behring | $197.98 | 2019-2025 | Haegarda, Hizentra |
| Mallinckrodt Hospital Products INC. | $135.36 | 2025 | Acthar |
| Optinose US, INC. | $135.08 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $135.05 | 2025 | Neffy |
| Amgen INC. | $122.83 | 2023 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $122.83 | 2023 | Tezspire |
| Genzyme Corporation | $104.20 | 2024 | |
| Octapharma USA, INC. | $66.72 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Dangelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.